Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - Regenicin, Inc. | ex10_1.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 25, 2015
REGENICIN, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 333-146834 | 27-3083341 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 10 High Court, Little Falls, NJ 07424 |
| Address of principal executive offices |
Registrant’s telephone number, including area code: (646) 403-3581
|
________________________________________________ (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION 1 – Registrant’s Business and Operations
Item 1.01 Entry into a Material Definitive Agreement
On February 25, 2015, we completed the final outstanding contractual arrangements under our Asset Purchase Agreement dated November 7, 2014 (the Agreement”) with Amarantus Bioscience Holdings, Inc. (“Amarantus”). As required under the Agreement, Amarantus has made the final payments due to us in the amount of $2,300,00.00, along with a payment of $200,000 to our senior secured creditor. In addition, we, along with Amaratus, have signed a Settlement Agreement in our lawsuit with Lonza Group, Ltd and its related entities (“Lonza”). As a result, we are currently in the process of filing a joint dismissal of all claims, known or unknown, in the Lonza matter.
The foregoing is a summary of the terms of the Settlement Agreement and is not a complete description of its terms. The full text of the Settlement Agreement, which is filed herewith as Exhibit 10.1, should be reviewed in it is entirety for further information.
Section 9 – Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
| Exhibit No. | Description |
| 10.1 | Settlement Agreement |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGENICIN, INC.
/s/ Randall McCoy
Randall McCoy
CEO and Director
Date: February 26, 2015
| 2 |